poisar

Stocks · News reference

FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial

Aug 27, 2026, 12:34 PMBenzinga Newsdesk

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FBLG
Source
benzinga
Observed
Aug 27, 2026, 12:34 PM
Checked
Aug 27, 2026, 12:34 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 24, 2026, 12:48 PMSEC EDGAR

    8-K filing — FibroBiologics, Inc. (FBLG)

    Filed: 2026-08-24 AccNo: 0001193125-26-362027 Size: 202 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    FBLG